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(2016Clinical presentations of inflammatory bowel disease:
East meets WestInflammatory bowel disease (IBD), including ulcerative
colitis (UC) and Crohn’s disease (CD), is a chronic condition
related to an intestinal mucosal immune response to antigenic
stimulation. Decades ago, IBD was a rare disease in Asia.
However, several recent population-based studies have shown
a rising trend in the prevalence of IBD in Asia.1e3 It has been
suggested that a Westernized diet and environment, as well as
lifestyle, may be primary causative factors of the upward
increment of IBD frequency in Asia. Also, differences in
clinical pictures are noted in IBD between Eastern and
Western patient populations. First of all, genetic mutations of
IBD in Asians differ from mutations in Caucasians. For
example, major nucleotide oligomerization domain (NOD)2,
interleukin (IL)-23 allele, and autophagy genetic variants
commonly identified in Caucasian IBD patients were not
detected in an Asian population.4 Furthermore, IBD patients in
Asia seem to have less familial clustering, milder disease
manifestation, lower rates of surgery, and lower rates of UC-
related colorectal cancer compared with the West.5
In Taiwan, research regarding IBD is scant, which might be
attributable to a previously low IBD incidence. Similar to
other countries in Asia, recent population studies from Taiwan
have already indicated an increasing trend in the incidence of
UC and CD.3,6 This observation may suggest a potentially
increasing burden of IBD on Taiwan’s healthcare system, and
local physicians should increase their familiarity with IBD.
The study by Hsu et al7 in this issue of the Journal of the
Chinese Medical Association compares the clinical data in UC
and CD from medical data extracted from the National Health
Insurance Research Database for the years 1998 to 2011. The
authors reconfirmed an increasing trend of IBD incidence in
Taiwan,3,6 which showed an approximate doubling from 1998
to 2011. Despite the increasing trend, the increment of IBD in
Taiwan seemed to be slower when compared with that of other
Asian countries. For example, in Korea, a large prospective
population-based epidemiological study showed at least a 10-
fold increase in the incidence of UC and CD in 2 decades,
which increased from 0.34/100,000 persons and 0.05/100,000
persons, respectively, from 1986 to 1990, to 3.08/100,000
persons and 1.34/100,000 persons, from 2001 to 2005.8 In
Japan, the incidence of UC and CD also increased from 0.08/x.doi.org/10.1016/j.jcma.2016.09.005
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100,000 persons and 0.51/100,000 persons in 1991 (a 20-fold
to 50-fold increase).2,9 There may exist some genetic, envi-
ronmental, or even gut microbiota factors responsible for the
slower increasing trend in IBD incidence in Taiwan, which
may deserve further evaluation.
The current study also found that the prevalences of colon
polyps and colorectal cancer (CRC) in UC patients in Taiwan
were lower than those from Western countries (polyp: 6.3%
vs. 14%; CRC: 0.39% vs. 3e5%).10 The authors suggest that
use of 5-aminosalicylic acid in UC treatment may prevent the
formation of adenomas.7 Other possible mechanisms may also
contribute to the observed phenomenon. Shorter durations of
follow-up of UC patients in the current study and less severe
disease activities compared with those from Western countries
may also contribute to a relatively lower prevalence in colon
polyps and CRC among UC patients. With the potential
increasing number of UC cases and increased duration of IBD
follow-up in Taiwan, it is probable that the prevalence of UC-
related polyps and CRC will also increase. This speculation
emphasizes the importance of colonoscopic surveillance with
biopsy among UC patients.
The current study reported an overall prevalence of
extraintestinal manifestations (EIMs) of 11.9% among the
IBD patients in Taiwan. The prevalence was similar to that
reported in East Asia (6e19%), which is significantly lower
compared to 25e40% in Western countries.11 Similar to the
reports from other Asian countries, joint manifestations are
the most commonly reported EIM in Taiwan, and primary
sclerosing cholangitis is also uncommon in the current
study.12 EIM of IBD can be more incapacitating than the
intestinal disease itself, significantly impairing the quality of
life in IBD patients. Actually, nearly every single organ can
be affected by EIM of IBD, and early recognition and ade-
quate treatment is necessary to prevent severe morbidity and
mortality in affected IBD patients.13 The reason behind the
low EIM in the IBD patients in Taiwan or other Asian
countries is unclear. Again, genetic or environmental factors
may play a role in the low EIM prevalence in IBD patients in
Taiwan. However, under-recognition of this condition may be
another potential factor for the phenomenon. It is necessarysevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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prevention and/or specific further treatment, which can have
a major benefit on patients’ quality of life.
In our case, the current study is valuable to demonstrate the
burgeoning trend and clinical manifestations of UC and CD in
Taiwan. Nevertheless, there still remains necessary research
that focuses on IBD in Taiwan or Asia. First of all, we need to
closely follow-up and define the IBD burden in Taiwan/Asia
so that we can notify healthcare providers regarding the
impact of issuance and allocation of resources in the disease
management. We also need to identify the potential causes of
IBD, and find the proper way to prevent its progression. Fur-
thermore, we need to establish the standard of care for IBD
patients in Taiwan/Asia. As noted above, the clinical mani-
festations in IBD patients present differently in Taiwanese/
Asian populations, and available clinical resources also differ
in Asia when compared to Western countries. Therefore, we
cannot incorporate all treatment guidelines from our counter-
part Western countries without modification. We therefore
need to set up a practical guideline for local use. However, we
believe further research should be undertaken in this rapidly
evolving field, which can ultimately lead to proper care and
management of our potentially rising IBD patient population,
not only in Taiwan, but also in Asia.
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